PBPriyanka Bajpai

Priyanka Bajpai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Priyanka Bajpai has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Flavonoid-Enriched Extract of Carissa carandas Linn Triggers Apoptosis and Cell Cycle Arrest in A549 Lung Cancer Cells: An Integrated In-Vitro and In-silico Approach Targeting CDK2 and Bcl-2

    by Priyanka Bajpai, Phool Chandra, Om Prakash

    Introduction: Carissa carandas Linn., a flavonoid-rich medicinal plant, has been reported to exhibit diverse pharmacological activities, including anticancer potential. Given that lung cancer remains one of the leading causes of cancer-related mortality worldwide and current chemotherapeutic regimens are often limited by toxicity and resistance, exploring plant-based alternatives offers a promising approach for developing safer and more effective anticancer therapies. This study was anticipated to evaluate the anticancer activity of ethanol-based extract of Carissa carandas leaves (EECC) on A549 human lung carcinoma cells, focusing on cytotoxicity, apoptosis induction, ROS generation, cell cycle arrest, and molecular interactions of key phytoconstituents with cancer-related targets, and to predict their pharmacokinetic and drug-likeness properties through in-silico methods. Materials and Methods: Phytochemical screening and antioxidant assays were performed initially. Cytotoxicity was assessed using the MTT assay, and apoptosis was confirmed by DAPI staining and Western blot analysis of apoptosis-related proteins (caspase-3, Bax, and Bcl-2). In-silico molecular docking was conducted using SwissDock for seven phytochemicals against cancer-related targets CDK2 and Bcl-2. SwissADME was employed to predict pharmacokinetic properties, including oral bioavailability, using bioavailability radar and BOILED-Egg models. results: EECC exhibited dose-dependent cytotoxicity with an IC₅₀ of 70.00 ± 1.50 µg/mL. Significant induction of apoptosis was observed, associated with elevated ROS levels (p < 0.01) and G0/G1 cell cycle arrest. Western blot analysis revealed upregulation of Bax and caspase-3 with concomitant downregulation of Bcl-2. Molecular docking identified Carindone and Quercetin as potent bioactive constituents showing strong binding affinities toward CDK2 and Bcl-2. SwissADME analysis confirmed favourable pharmacokinetic and oral bioavailability profiles of these compounds. Results: EECC demonstrated dose-dependent cytotoxicity (IC50 of 87.96 ± 0.64 μg/mL). Apoptotic markers showed increased Bax and caspase-3 levels and decreased expression of Bcl-2. Apoptosis was significantly induced at increasing concentrations, correlating with elevated ROS levels (p < 0.01) and G0/G1 phase arrest. Docking analysis identified Carindone and Quercetin as key bioactive compounds, with strong binding affinities to CDK2 and Bcl-2. ADME analysis revealed favourable drug-likeness and oral bioavailability profiles for these compounds. Discussion: The findings suggest that EECC exerts anticancer effects against A549 lung carcinoma cells primarily through ROS-mediated apoptosis and cell cycle arrest. The molecular docking outcomes strengthen the experimental observations by highlighting Carindone and Quercetin as potential modulators of cancer-associated proteins. The consistency between in-vitro and in-silico analyses underscores the therapeutic potential of EECC and its phytoconstituents as promising anticancer leads. Conclusion: EECC suppresses A549 lung cancer cell growth via ROS-mediated apoptosis and cell cycle arrest. Computational studies support these findings, identifying Carindone and Quercetin as promising lead compounds with desirable pharmacokinetic properties. These results warrant further in vivo and clinical analysis to explore the therapeutic potential of EECC in lung cancer treatment.

  • Integrative In Vitro and In Silico Evaluation of Flavonoid-enriched Carica papaya Linn. Extract Targeting Oncogenic Pathways in A549 Lung Cancer Cells

    by Priyanka Bajpai, Phool Chandra, Om Prakash

    Introduction: Non-Small Cell Lung Carcinoma (NSCLC) specifically is still one of the top causes of cancer-related death globally. The multi-targeted mechanisms and lower toxicity of natural products make them intriguing pharmacological candidates. Using a combination of in vitro and in silico methods, the current study assessed the anticancer potential of the Ethanol Extract of Carica papaya Linn. roots (EECP). Methods: Phytochemical profiling and High-Performance Thin-Layer Chromatography (HPTLC) analysis confirmed the presence of flavonoids, including rutin. The 2,2-diphenyl-1- picrylhydrazyl (DPPH) assay was used to assess antioxidant activity. Cytotoxicity against Human lung adenocarcinoma cell line (A549) and normal human lung fibroblast cell line (WI-38) cells was evaluated, along with apoptosis via nuclear condensation, Deoxyribonucleic Acid (DNA) fragmentation, and Reactive Oxygen Species (ROS) accumulation. Molecular docking (SwissDock) and Absorption, Distribution, Metabolism, and Excretion (ADME) predictions were performed to assess protein interactions, drug-likeness, and oral bioavailability. results: EECP exhibited strong antioxidant activity (IC₅₀ = 4.07 μg/mL) and selective cytotoxicity toward A549 cells (IC₅₀ = 89.96 ± 0.24 μg/mL) with lower toxicity in WI-38 fibroblasts. Treatment induced significant ROS generation (213% at 300 μg/mL) and apoptotic changes. Docking studies revealed strong interactions of quercetin (–9.758 kcal/mol) and kaempferol (–9.353 kcal/mol) with oncogenic proteins, comparable to staurosporine (–10.439 kcal/mol). ADME predictions supported favorable bioavailability and drug-likeness. Results: Ethanolic extract demonstrated potent antioxidant activity (IC50 = 4.07 μg/mL) and selective cytotoxicity against A549 cells (IC50 = 89.96±0.24 μg/mL), with comparatively lower toxicity in WI-38 cells (IC50 = 75.83±0.34 μg/mL). Apoptosis was associated with nuclear condensation, DNA fragmentation, and a 213% increase in ROS at 300 μg/mL. Docking studies indicated strong binding of quercetin (-9.758 kcal/mol) and kaempferol (-9.353 kcal/mol) to oncogenic proteins, comparable to that of staurosporine (-10.439 kcal/mol), mediated by hydrogen bonds and hydrophobic interactions. Phenolic acids showed moderate interactions, and carpaine/ ergosta derivatives showed weaker interactions. ADME analyses revealed favourable oral bioavailability and high gastrointestinal absorption for key flavonoids. Discussion: Ethanolic extract induces oxidative stress-mediated apoptosis and regulates key signalling proteins, including Protein Kinase B (Akt) and tumor suppressor p53 (p53). Conclusion: Overall, the EECP exhibits strong anticancer potential by inducing ROS-mediated apoptosis and regulating Akt and p53, supporting further preclinical evaluation of C. papaya Linn. root flavonoids for lung cancer.

  • Pharmacokinetics and Pharmacodynamics of Natural Products in Oncology: Bridging the Gap between Promise and Clinical Reality

    by Priyanka Bajpai, Phool Chandra, Om Prakash

    Introduction: Natural products have historically contributed to cancer therapeutics, leading to agents like paclitaxel and vincristine. Recently, compounds such as curcumin, resveratrol, quercetin, and berberine have gained attention due to their multitargeted mechanisms and favorable safety profiles. However, their clinical application remains limited owing to significant pharmacokinetic (PK) and pharmacodynamic (PD) challenges. This review aims to highlight these limitations and explore emerging strategies to enhance their oncotherapeutic potential. Methods: A comprehensive literature review was conducted using peer-reviewed articles and clinical trial reports from databases including PubMed, Scopus, and Web of Science. Key PK/PD limitations and advanced formulation approaches were identified and critically analyzed. Results: Major PK barriers include poor oral bioavailability, low solubility, rapid metabolism, and short half-life. PD challenges involve multi-target effects, inconsistent doseresponse relationships, and a lack of validated biomarkers. Examples include curcumin’s poor bioavailability and resveratrol’s rapid metabolism. Emerging strategies such as nanotechnology-based delivery systems, prodrug development, structural modifications, and co-administration with bioavailability enhancers, such as piperine, have shown promise. Success stories such as Abraxane® (albumin-bound paclitaxel) and topotecan (a camptothecin derivative) illustrate effective translational approaches. Discussion: Overcoming PK/PD limitations is essential for translating natural compounds into effective oncotherapeutics. Integrating nanomedicine, chemical modifications, and bioenhancers improves pharmacological profiles. Conclusion: Future directions should combine pharmacogenomics, nanotechnology, and AI-driven drug discovery to enhance the clinical relevance of natural anticancer agents. For example, AI-guided structural optimization of camptothecin analogs (e.g., topotecan) and nanoparticle-based formulations such as Abraxane® demonstrate how computational and translational innovations can successfully advance natural products into clinical oncology.

  • Harnessing the Therapeutic Attributes of Nutraceuticals in Cancer Management: Mechanisms, Evidence, and Future Directions

    by Om Prakash, Priyanka Bajpai

    Objective: Cancer is a complex disease with a multifactorial aetiology, demanding a holistic approach to treatment. In recent years, there has been growing interest in the po-tential role of nutraceuticals as adjunctive or alternative therapies for cancer management. Methods: A comprehensive literature review was conducted, analyzing epidemiological studies, mode of action, and preclinical and clinical evidence, that investigate the correlation between nutraceuticals consumption and reduced cancer risk. The mechanisms through which nutraceuticals exert anti-tumour effects were examined, including their impact on mo-lecular pathways and specific targets in cancer cells. Results: Nutraceuticals, which include bioactive compounds derived from natural sources such as fruits, vegetables, herbs, and spices, have demonstrated promising anti-cancer prop-erties through various mechanisms, including antioxidant, anti-inflammatory, antiprolifera-tive, and pro-apoptotic effects. Conclusion: This comprehensive review examines the current evidence regarding the effi-cacy and safety of various nutraceuticals in cancer treatment, highlighting their potential mechanisms of action, preclinical and clinical studies, as well as challenges and future di-rections in this rapidly evolving field.


  • Emerging Anti-Inflammatory Attributes of Curcumin: A Novel Paradigm and Ameliorative Attributes for the Treatment of Osteoarthritis

    by Priyanka Bajpai, Phool Chandra

    Strong oxidant, curcumin, is diferuloyl methane; a member of the class of phenols known as curcuminoids that give Indian medicinal plants their characteristic turmeric-yellow hue. Over 5000 years ago, curcumin was first employed in the traditional Indian medical system. A growing amount of investigation reveals that curcumin has several pharmacological characteristics, including anticancer, hepatoprotective, anti-inflammatory, antioxidant, and antibacterial properties. Clinical tests revealed no harm, but some participants did have moderate nausea or diarrhea. A degenerative joint condition known as osteoarthritis affects elderly populations all over the world. It has a chronic inflammatory etiology, which contributes to chondrocyte loss that results in a thinner surface of cartilage at the affected joints. Curcumin has been scientifically demonstrated to exhibit medicinal benefits for osteoarthritis (OA), and further research is being conducted on the numerous ways through which it suppresses inflammation and slows the progression of ailments. Clinical and preclinical studies suggest the potential efficacy of curcumin in managing osteoarthritis, warranting further investigation. With emphasis on the mechanisms associated, this review seeks to completely outline the clinical effectiveness of curcumin using data from a variety of scientific studies that have been published so far.


  • Relevance of Conventional Herbal Remedies in the Prevention and Treatment of Malignant Tumors: Looking Toward the Future

    by Priyanka Bajpai, Phool Chandra

    : The second most prevalent cause of fatalities globally is malignant tumors. The avoidance and therapy of cancer proliferation still have many prospects for betterment despite enormous advancements. Chemotherapy can occasionally have a lot of unfavorable adverse reactions. Novel agents from botanicals, especially the use of cancer therapeutic ingredients, may decrease negative consequences. There are currently several products from plants used for fighting cancer. However, numerous plant chemicals have not yet been examined in people but show extremely encouraging invitro anti-cancer properties. Further research is required to determine whether these plant chemicals are beneficial in treating human cancers. The present work has focused on the various traditional herbal remedies and the phytochemicals that exhibited promising anticancer impact. The desirable activity may be due to novel agents isolated from plant sources. The present investigations address natural ingredients for cancer treatment and chemoprevention that are now being used in clinical settings and/or are undergoing clinical studies. Potential research concentrating on naturally anticancer drugs can create an entirely novel avenue in the fight against cancer that could significantly boost the chance of survival for cancer patients.


  • Open Access

    The versatility of apigenin: Especially as a chemopreventive agent for cancer

    by Om Prakash, Amit Kumar, Salil Tiwari, Priyanka Bajpai


  • Treatment of Scabies with Herbal Medicines

    by Om Prakash, Priyanka Bajpai, Shazia Usmani, Ruchi Singh, Amita Pandey, Rajesh Kumar, Nadeem Rais

    Scabies is a chronic and serious community disorder caused by a parasite commonly known as a mite (Sarcoptes scabiei var hominis). The long-term infection may lead to chronic complications such as septicemia, acute post-streptococcal glomerulonephritis, heart disease, and secondary infections. The majority of novel medicinal agents from various plant sources are responsible for the management and treatment of several types of chronic disorders. The safe and cost-effective alternative treatment strategy is the use of medicinal plants that plays a potential role against a variety of diseases due to the presence of numerous types of active phytochemicals with no or negligible adverse effect. This study gives a unique summary, including a correlation between traditional medicinal plants and their derived active phytochemicals for the significant treatment of scabies. The literature search was carried out via search engines through different databases, including Google Scholar, PubMed, Medline, ScienceDirect, etc. A large number of medicinal plants and their active medicinal agents have been reviewed with remarkable therapeutic effects against scabies. There are some limitations due to insufficient data related to limited pre-clinical and clinical trials in this particular area. This review provides a baseline to explore the therapeutic potential of these medicinal plants against skin diseases, especially scabies. However, extensive studies are required to identify, authenticate, and characterize the bioactive compounds present in these plants, which may lead to value addition in pharmaceutical industries by providing a cost-effective way of treatment with minimal side effects.